EFFICACY OF PIRFENIDONE ON DYSPNEA IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): RESULTS FROM A POST HOC RESPONDER ANALYSIS

被引：0
|
作者：
Glassberg, Marilyn K.
Thavarajah, Krishna
Collins, Bridget F.
Gupta, Sachin
Trzaskoma, Benjamin
Kirchgaessler, Klaus-Uwe
Devine, Jacob
Raghu, Ganesh
机构：
来源：
CHEST | 2022年 / 162卷 / 04期
关键词：
D O I：
10.1016/j.chest.2022.08.996
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1246A / 1247A
页数：2
相关论文
共 50 条
  • [31] Multicenter Population Pharmacokinetics and Exposure–Efficacy Analysis of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    Peile Wang
    Hui Li
    Shanshan Chen
    Han Xing
    Jing Yang
    Guojun Zhang
    Xiaojian Zhang
    Clinical Pharmacokinetics, 2023, 62 : 921 - 930
  • [32] Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
    Li, Hui
    Yang, Jing
    Chen, Shanshan
    Wang, Peile
    Yu, Xueqing
    Zhou, Qingwei
    Zhang, Xiaojian
    Zhang, Guojun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [33] Analysis of Patients With Idiopathic Pulmonary Fibrosis (IPF) With More Severe Lung Function Impairment Treated With Pirfenidone in Recap
    Costabel, Ulrich
    Albera, Carlo
    Kirchgaessler, Klaus-Uwe
    Gilberg, Frank
    Petzinger, Ute
    Ruhrlandklinik, Paul Noble
    CHEST, 2016, 150 (04) : 537A - 537A
  • [34] Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)
    Costabel, Ulrich
    Albera, Carlo
    Lancaster, Lisa
    Hormel, Phillip
    Hulter, Henry
    Noble, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [35] Clinical significance of serum SP-D as a biomarker for antifibrotics in idiopathic pulmonary fibrosis (IPF): Post hoc analysis of a phase 3 trial of pirfenidone in Japan
    Chiba, Hirofumi
    Ikeda, Kimiyuki
    Azuma, Arata
    Kondoh, Yasuhiro
    Ogura, Takashi
    Taguchi, Yoshio
    Ebina, Masahito
    Miyazawa, Shogo
    Sakaguchi, Hiroki
    Suga, Moritaka
    Sugiyama, Yukihiko
    Nukiwa, Toshihiro
    Kudoh, Shoji
    Takahashi, Hiroki
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [36] Longitudinal trends in dyspnea in patients with idiopathic pulmonary fibrosis (IPF): The build I study
    Swigris, Jeff
    Behr, Juergen
    Brown, Kevin
    duBois, Ron
    King, Talmadge, Jr.
    Raghu, Ganesh
    CHEST, 2006, 130 (04) : 282S - 282S
  • [37] Efficacy of Pirfenidone in Patients with Advanced-stage Idiopathic Pulmonary Fibrosis
    Sakamoto, Susumu
    Itoh, Takafumi
    Muramatsu, Yoko
    Satoh, Keita
    Ishida, Fumiaki
    Sugino, Keishi
    Isobe, Kazutoshi
    Homma, Sakae
    INTERNAL MEDICINE, 2013, 52 (22) : 2495 - 2501
  • [38] ANTACID THERAPY AND DISEASE PROGRESSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) UNDER PIRFENIDONE TREATMENT
    Kreuter, M.
    Spagnolo, P.
    Wuyts, W.
    Renzoni, E.
    Koschel, D.
    Bonella, F.
    Maher, T. M.
    Kolb, M.
    Weycker, D.
    Kirchgassler, K.
    Costabel, U.
    THORAX, 2016, 71 : A58 - A58
  • [39] Safety, Tolerability and Efficacy of Nintedanib Switched from Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    Ikeda, S.
    Sekine, A.
    Baba, T.
    Katano, T.
    Matama, G.
    Aiko, N.
    Isomoto, K.
    Otoshi, R.
    Tabata, E.
    Shintani, R.
    Sadoyama, S.
    Yamakawa, H.
    Niwa, T.
    Nakagawa, H.
    Oda, T.
    Okuda, R.
    Kitamura, H.
    Komatsu, S.
    Hagiwara, E.
    Ogura, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [40] Post-hoc analysis of clinical characteristics and outcomes in patients with idiopathic pulmonary fibrosis (IPF) by elevated autoantibody (AAb) status
    Newton, C.
    Kulkarni, T.
    Samara, K.
    Ko, J.
    Gupta, S.
    Bernstein, E. J.
    Samara, A. D.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
12345